BiotechTube

TNX-103 + Placebo

Phase 3Recruiting
0 views this week 0 watching⚡ Active
Interest: 44/100
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Pulmonary Hypertension

Conditions

Pulmonary Hypertension

Trial Timeline

Jan 10, 2024 → Oct 1, 2028

NCT ID
NCT05983250

About TNX-103 + Placebo

TNX-103 + Placebo is a phase 3 stage product being developed by Medpace for Pulmonary Hypertension. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05983250. Target conditions include Pulmonary Hypertension.

What happened to similar drugs?

20 of 20 similar drugs in Pulmonary Hypertension were approved

Approved (20) Terminated (1) Active (0)
✅MonteplaseEisaiApproved
✅lysozyme 90 mg + PlaceboEisaiApproved
✅tadalafil and ambrisentan upfront combination therapyEli LillyApproved
✅Arformoterol tartrate + Placebo: Normal SalineSumitomo PharmaApproved
✅Arformoterol tartrate inhalation solution + TiotropiumSumitomo PharmaApproved
✅Nebulized arformoterol + SalmeterolSumitomo PharmaApproved
✅Arformoterol Tartrate Inhalation Solution + Arformoterol Tartrate Inhalation Solution + PlaceboSumitomo PharmaApproved

Hype Score Breakdown

Clinical
17
Activity
15
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05983250Phase 3Recruiting

Competing Products

20 competing products in Pulmonary Hypertension

See all competitors
ProductCompanyStageHype Score
AP01Avalyn PharmaceuticalsPhase 2
32
macitentan 10 mgBML, Inc.Phase 3
32
tadalafil + tadalafilEli LillyPhase 3
40
CS1 AdministrationCereno ScientificPhase 2
29
CS1Cereno ScientificPre-clinical
24
TX000045- Dose A + TX000045- Dose B + PlaceboTectonic TherapeuticPhase 2
36
Dose A KER-012 + Dose B KER-012 + Dose C KER-012 + Placebo for 24 Weeks followed by Dose B KER-012 for 72 weeksKeros TherapeuticsPhase 2
25
Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03) + PlaceboRein TherapeuticsPhase 1
19
LTI-03 + PlaceboRein TherapeuticsPhase 1
19
LTI-03 + PlaceboRein TherapeuticsPhase 2
32
Satralizumab (Genetical Recombination)Chugai PharmaceuticalPhase 2
39
DS-1040b + Placebo + EnoxaparinDaiichi SankyoPhase 1/2
32
DS-9231 + PlaceboDaiichi SankyoPhase 2
27
RegadenosonAstellas PharmaPre-clinical
18
Reldesemtiv + PlaceboAstellas PharmaPhase 2
35
MonteplaseEisaiApproved
43
lysozyme 90 mg + PlaceboEisaiApproved
43
Prednisolone + VoriconazoleCiplaPhase 2/3
38
Drotrecogin Alfa (Activated) + Enoxaparin + Placebo + Drotrecogin Alfa (Activated) + Drotrecogin Alfa (Activated) + Drotrecogin Alfa (Activated)Eli LillyPhase 2
35
tadalafil and ambrisentan upfront combination therapyEli LillyApproved
43